Ezutromid

Drug Profile

Ezutromid

Alternative Names: BMN-195; SMT-1100; SMTC-1100; VOX-C1100

Latest Information Update: 18 Nov 2016

Price : $50

At a glance

  • Originator VASTox
  • Developer Summit Therapeutics
  • Class Benzoxazoles; Naphthalenes; Small molecules; Sulfoxides
  • Mechanism of Action Utrophin activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Duchenne muscular dystrophy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy

Most Recent Events

  • 16 Nov 2016 Phase-II clinical trials in Duchenne muscular dystrophy (In children) in USA (PO)
  • 04 Oct 2016 Summit Therapeutics and Sarepta Therapeutics agree to co-develop ezutromid in Turkey, Common Wealth of Independent States and Europe for Duchenne muscular dystrophy
  • 27 Sep 2016 Ezutromid receives Rare Paediatric Disease designation for Duchenne muscular dystrophy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top